| GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC) | GASC1 Inhibitor Caffeic Acid for Advanced Squamous Esophageal Cell Cancer (ESCC): a Multicenter, Phase II Trial (GiCAEC) | NCT04648917 |
| Caffeic Acid Combining High-dose Dexamethasone in Management of ITP | A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) | NCT02556814 |
| Efficacy and safety of caffeic acid in improvingmetabolic dysfunction associatedfatty liver disease | Efficacy and safety of caffeic acid in improving hepatic steatosis and metabolic disorders in patients with metabolic dysfunction associatedfatty liver disease | ChiCTR2100052729 |
| evaluation of the effect of caffeic acid on recurrent aphthous stomatitis improvement | evaluation of the effect of caffeic acid on recurrent aphthous stomatitis improvement | IRCT20220815055700N1 |
| Treatment of minimal hepatic encephalopathy with berberine and caffeic acid | Berberine and caffeic acid in the treatment of mild hepatic encephalopathy: a randomized open-labled parallel controlled prospective study | ChiCTR2100052806 |
| A single-arm, single-center exploratory clinical study of Herombopag Olamine Tablets in combination with Caffeic acid Tablets for the treatment of cancer therapy-induced thrombocytopenia | A single-arm, single-center exploratory clinical study of Herombopag Olamine Tablets in combination with Caffeic acid Tablets for the treatment of cancer therapy-induced thrombocytopenia | ChiCTR2400086043 |
| Caffeic Acid Tablets as a Second-line Therapy for ITP | A Multicentre Randomized Study of Caffeic Acid Tablets as a Second-line Therapy for the Treatment of Immune Thrombocytopenia (ITP) | NCT02351622 |
